8 completed, 6 active not recruiting, 3 recruiting, 3 terminated. 19 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
By phase and status
Follow ezabenlimab: new trials by email Literature Review of ezabenlimab trials Research Report on ezabenlimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
BI 3968621, ezabenlimab - Advanced Solid Tumour | Phase 1 | Recruiting | 90 | 2026-10-26 | 2026-10-28 |
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
BI 3923948, Ezabenlimab - Solid Tumors | Phase 1 | Suspended | 60 | 2026-04-02 | 2026-10-13 |
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | | 2024-06-27 | 2024-07-17 |
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
BI 765049, Ezabenlimab - Gastrointestinal Cancer, Lung Cancer | Phase 1 | Terminated | 21 | 2024-02-16 | 2026-10-14 |
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Obrixtamig, Ezabenlimab - Small Cell Lung Carcinoma (SCLC), Neuroendocrine Neoplasms | Phase 1 | Active not recruiting | 45 | 2023-06-27 | 2026-10-27 |
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
VSV-GP154, ATP150, ATP152 - Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | 59 | 2023-05-11 | 2026-08-14 |
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
BI 1703880, Ezabenlimab - Solid Tumors | Phase 1 | Recruiting | 66 | 2023-02-24 | 2026-11-02 |
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
Ezabenlimab, BI 765063, Pembrolizumab - Colorectal Cancer | Phase 1 | Terminated | 2 | 2022-09-27 | 2025-03-13 |
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
BI 770371, ezabenlimab - Solid Tumors | Phase 1 | Active not recruiting | 42 | 2022-05-17 | 2026-09-01 |
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
BI 765063, Ezabenlimab, BI 836880 - Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 | Completed | 48 | 2022-04-12 | 2026-09-16 |
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063 - Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma | Phase 1 | Active not recruiting | 14 | 2022-03-03 | 2026-09-30 |
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
BI 765179, Ezabenlimab, Pembrolizumab - Neoplasms | Phase 1 | Active not recruiting | 151 | 2021-10-18 | 2026-10-27 |
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
BI 765049, ezabenlimab - Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms | Phase 1 | Completed | 67 | 2021-05-18 | 2026-02-02 |
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
BI 1387446 50 μg, BI 754091, BI 1387446 100 μg - Neoplasms | Phase 1 | Completed | 42 | 2020-08-03 | 2025-08-19 |
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
ATP128, BI 754091, VSV-GP128 - Colorectal Cancer, MSS | Phase 1 | Active not recruiting | 96 | 2019-07-22 | 2025-01-29 |
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
BI 907828, ezabenlimab, BI 754111 - Neoplasms | Phase 1 | Completed | 119 | 2019-06-20 | 2026-02-18 |
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | 211 | 2019-03-19 | 2026-01-27 |
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
BI 754111, [89Zr]Zr-BI 754111, BI 754091 - Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms | Phase 1 | Terminated | 8 | 2019-01-22 | 2026-01-13 |
A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
BI 836880, Ezabenlimab - Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms | Phase 1 | Completed | 252 | 2018-07-05 | 2025-11-10 |
This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer
Ezabenlimab, BI 754111 - Neoplasms | Early Phase 1 | Completed | 146 | 2018-02-23 | 2025-12-19 |
Showing 20 of 22. Sign in to see all of them.
Conditions studied
Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Head and Neck Neoplasms (3) · Carcinoma (2) · Gastrointestinal Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Colonic Neoplasms (1) · Dermatofibrosarcoma (1) · Glioblastoma (1) · Histiocytoma, Malignant Fibrous (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1)
Sponsors
Boehringer Ingelheim (20) · Amal Therapeutics (1) · Johann Wolfgang Goethe University Hospital (1)
Countries
United States (15) · Japan (9) · Spain (9) · Germany (7) · United Kingdom (7) · France (6) · Belgium (5) · Canada (4) · Netherlands (4) · South Korea (4) · Australia (3) · Poland (3) · Taiwan (3) · Mexico (2) · Switzerland (2)
Top investigators
Michael C Burger, PD Dr. med. (1) · Scott Kopetz (1)
Results publications
PMID 35756842, PMID 36859619, PMID 38314087, PMID 39817655
NIH funding
2017 (3), 2019 (3), 2018 (1), 2023 (1), 2025 (1)